Algernon Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 5/6
Algernon Pharmaceuticals has a total shareholder equity of CA$2.0M and total debt of CA$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are CA$3.9M and CA$1.9M respectively.
Key information
0%
Debt to equity ratio
CA$0
Debt
| Interest coverage ratio | n/a |
| Cash | CA$609.52k |
| Equity | CA$1.96m |
| Total liabilities | CA$1.93m |
| Total assets | CA$3.89m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: AGN's short term assets (CA$687.0K) do not cover its short term liabilities (CA$1.9M).
Long Term Liabilities: AGN has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: AGN is debt free.
Reducing Debt: AGN has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AGN has sufficient cash runway for 3 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: AGN is forecast to have sufficient cash runway for 3 months based on free cash flow estimates, but has since raised additional capital.